Metagenomi Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Brian C. Thomas and Pamela Wapnick, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof
Pursuant to the requirements of the Securities Act, this Annual Report on Form 10-K has been signed by the following person in the capacities and on the date indicated.
| NAME | TITLE | DATE |
|---|---|---|
| /s/ Brian C. Thomas | Chief Executive Officer and Director | March 17, 2025 |
| Brian C. Thomas, Ph.D. | (Principal Executive Officer) | |
| /s/ Pamela Wapnick | Chief Financial Officer | March 17, 2025 |
| Pamela Wapnick, M.B.A. | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Jian Irish | President, Chief Operating Officer and Director | March 17, 2025 |
| Jian Irish, Ph.D., M.B.A. | ||
| /s/ Sebastián Bernales | Director | March 17, 2025 |
| Sebastián Bernales, Ph.D. | ||
| /s/ Eric Bjerkholt | Director | March 17, 2025 |
| Eric Bjerkholt, M.B.A. | ||
| /s/ Willard Dere | Director | March 17, 2025 |
| Willard Dere, M.D. | ||
| /s/ Juergen Eckhardt | Director | March 17, 2025 |
| Juergen Eckhardt, M.D., M.B.A. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Operations for the Years ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Cash Flows for the Years ended December 31, 2024 and 2023 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.